When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

JAKARTA, INDONESIA - Media OutReach Newswire - 9 January 2025 - Novo Nordisk and AstraZeneca have been recognized as the top ...

Comparing Tyrzepatide and Semaglutide in the slimming drug market, with potential growth driven by increasing obesity rates worldwide. Explore more here.

Diabetes drugs now represent over 75% of total sales in the metabolic disorders market, up from below 40% ten years ago. The ...

Bernstein upgraded Novo Nordisk (NYSE:NVO) to “Market Perform” with a stock price of $84.86. The company’s stock shows slight ...

Given that more than 40% of Indian adults are struggling with obesity and diabetes, affordable weight-loss drugs are expected ...

Novo Nordisk has started building ... up 3% on the same period of 2023 - but Novo Nordisk has a stated ambition of generating a "sustained growth outlook" for the business as sales of some ...

Novo Nordisk has ... version of parathyroid hormone (PTH), which is for the treatment of hypoparathyroidism in adults, and Skytrofa (lonapegsomatropin), a long-acting growth hormone for children ...

Vancouver-based Aspect Biosystems has raised a $115-million USD ($165 million CAD) Series B round to realize its ambitions of ...